Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common stock, $0.0001 par value per share
-
Shares outstanding
-
75.9M
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
38.8M
-
Shares change
-
+38.7M
-
Total reported value, excl. options
-
$1.7B
-
Value change
-
+$1.7B
-
Number of buys
-
94
-
Price
-
$43.90
Significant Holders of CG Oncology, Inc. - Common stock, $0.0001 par value per share (CGON) as of Q1 2024
97 filings reported holding CGON - CG Oncology, Inc. - Common stock, $0.0001 par value per share as of Q1 2024.
CG Oncology, Inc. - Common stock, $0.0001 par value per share (CGON) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.8M shares
of 75.9M outstanding shares and own 51.11% of the company stock.
Largest 10 shareholders include Decheng Capital LLC (5.46M shares), TCG Crossover Management, LLC (3.57M shares), BlackRock Inc. (2.52M shares), VANGUARD GROUP INC (2.23M shares), BVF INC/IL (1.88M shares), JANUS HENDERSON GROUP PLC (1.52M shares), Avidity Partners Management LP (1.45M shares), RA CAPITAL MANAGEMENT, L.P. (1.4M shares), PERCEPTIVE ADVISORS LLC (1.3M shares), and BRAIDWELL LP (1.13M shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.